Contribute Try STAT+ Today

Well, this is stunning: Looks like Grail, the Illumina spinout that’s working on an early blood-based screening test for cancer, will be raising a Series B round that clocks in at more than $1 billion.

The company just put out a statement that a number of undisclosed investors are seriously interested in doling out this cash. Fast Company last month had reported that the company was looking to raise $1.7 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Link exchange is nothing else but it is just placing the other person’s website link on your page at appropriate place and other person will also do same in support of you.

Comments are closed.